ACS Medicinal Chemistry Letters · 2015 · 21 citations · 19 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryProdrug DesignDrug DispositionEnzymatic Cleavage StrategiesEnzyme InhibitionPharmacokinetics Of AntimicrobialsSolubility OptimizationTopoisomerase InhibitorsAntibacterial ProdrugsAntibacterial PropertiesAqueous Solubility ImprovementAqueous Solubility OptimizationOptimization Of Drug-like PropertiesProdrug Design For SolubilitySmall Molecule Drug DesignSmall Molecule Drug Development
Benzimidazole 1 is the lead compound resulting from an antibacterial program targeting dual inhibitors of bacterial DNA gyrase and topoisomerase IV. With the goal of improving key drug-like properties, namely, the solubility and the formulability of 1, an effort to identify prodrugs was undertaken. This has led to the discovery of a phosphate ester prodrug 2. This prodrug is rapidly cleaved to the parent drug molecule upon both oral and intravenous administration. The prodrug achieved equivalent exposure of 1 compared to dosing the parent in multiple species. The prodrug 2 has improved aqueous solubility, simplifying both intravenous and oral formulation.
19
Alkaline phosphatase isoenzymes.
D.W. Moss · Clinical Chemistry · 1982 · 348 citations
Paul S. Charifson, Anne‐Laure Grillot, Trudy H. Grossman et al. · Journal of Medicinal Chemistry · 2008 · 225 citations · Full text